Recombinant Human Gamma-Interferon in Primary Hepatocellular Carcinoma | Zendy

Alastair Forbes | Zendy; Philip J. Johnson | Zendy; Roger Williams | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Recombinant Human Gamma-Interferon in Primary Hepatocellular Carcinoma

Author(s) -

Alastair Forbes,

Philip J. Johnson,

Roger Williams

Publication year - 1985

Publication title -

journal of the royal society of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.38

H-Index - 81

eISSN - 1758-1095

pISSN - 0141-0768

DOI - 10.1177/014107688507801007

Subject(s) - hepatocellular carcinoma , recombinant dna , medicine , toxicity , carcinoma , interferon , interferon gamma , renal cell carcinoma , oncology , immunology , gastroenterology , cytokine , biology , biochemistry , gene

A phase II trial of recombinant human gamma-interferon in the treatment of unresectable primary hepatocellular carcinoma is reported. The trial was terminated prematurely after recruitment of only 7 patients because of unacceptable toxicity, predominantly renal. There was no evidence of response in any of the 7 patients but some evidence that disease progression was more rapid during the treatment period.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research